Dar Bioscience enters into an agreement w/ CONRAD in connection with a postcoital test Ovaprene, wherein CONRAD will provide certain clinical and regulatory services related to the PCT clinical trial that Dar will sponsor :
Dar intends to commence a PCT clinical trial of Ovaprene with CONRAD, and this memorandum of understanding is an important step in the series of study initiation activities, that will include manufacturing as well as other clinical trial related activities, to prepare for enrolling the first subjects in the PCT clinical trial in early 2018.
- Based on current projections, Dar believes it is adequately funded to advance Ovaprene through the completion of the PCT clinical trial within the next two years.
- A successful PCT clinical trial outcome would represent a meaningful milestone and should allow Dar to proceed directly to a pivotal contraceptive efficacy trial in the United States.
No comments:
Post a Comment